The evolution of neuromyelitis optica spectrum disorder (NMOSD) from a rare, incurable and misunderstood disease with almost universally poor outcomes to its present state in just over a decade is unprecedented in neurology and possibly in medicine. Our knowledge of NMOSD biology has led to the recognition of wider phenotypes, new disease mechanisms, and thus clinical trials of new and effective treatments. This article aims to update readers on the recent developments in NMOSD with particular emphasis on clinical advances, the 2015 diagnostic criteria, biomarkers, imaging, and therapeutic interventions.
CITATION STYLE
Whittam, D., Wilson, M., Hamid, S., Keir, G., Bhojak, M., & Jacob, A. (2017). What’s new in neuromyelitis optica? A short review for the clinical neurologist. Journal of Neurology, 264(11), 2330–2344. https://doi.org/10.1007/s00415-017-8445-8
Mendeley helps you to discover research relevant for your work.